Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha

Acute promyelocytic leukemia, arsenic, and PML bodies

(2012) Hugues de Thé et al.   JOURNAL OF CELL BIOLOGY

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression

(2012) Christian Schürch et al.   JOURNAL OF CLINICAL INVESTIGATION

Leucémie myéloïde chronique : « archétype » de l’impact des traitements ciblés

(2012) R. Nasr et al.   PATHOLOGIE BIOLOGIE

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

How I treat adult T-cell leukemia/lymphoma

(2011) A. Bazarbachi et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

(2011) S.-J. Chen et al.   BLOOD

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML

(2011) G. V. Helgason et al.   BLOOD

Curing APL through PML/RARA degradation by As2O3

(2011) Valerie Lallemand-Breitenbach et al.   TRENDS IN MOLECULAR MEDICINE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The response to imatinib and interferon-  is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

(2010) F. Palandri et al.   HAEMATOLOGICA

Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting

(2010) Rihab Nasr et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

(2010) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia

(2010) Hiba El Hajj et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia

(2010) Makoto Kashimura et al.   LEUKEMIA RESEARCH

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

(2010) Franck E. Nicolini et al.   LEUKEMIA RESEARCH

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia

(2010) J.-H. Mao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PML Nuclear Bodies

(2010) V. Lallemand-Breitenbach et al.   Cold Spring Harbor Perspectives in Biology

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)

(2009) G. Kchour et al.   BLOOD

Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure

(2009) R. Nasr et al.   CLINICAL CANCER RESEARCH

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

The tumor suppressor Pml regulates cell fate in the developing neocortex

(2009) Tarik Regad et al.   NATURE NEUROSCIENCE

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

(2008) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE

Therapy Options in Imatinib Failures

(2008) P. Ramirez et al.   ONCOLOGIST